STOCK TITAN
  1. Home
  2. News
  3. ABT

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated news page for Abbott Laboratories (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbott Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbott Laboratories's position in the market.

News
New Study Shows Mixed Reality Technology for Blood Donation From Abbott and Blood Centers of America Helps Ease Stress, Encourages People To Donate Again
Rhea-AI Summary
Abbott (NYSE:ABT) and Blood Centers of America (BCA) have partnered to launch a mixed reality experience for blood donors, designed to ease feelings of anxiety and increase donor retention. Results from the pilot study show that 68.4% of donors who reported pre-donation anxiety felt less anxious using mixed reality, and 89.2% of donors said they were likely to donate blood again. The technology aims to attract new donors and motivate a younger generation to give blood, addressing the global challenge of sustaining a reliable blood supply.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
News
Decade of Impact: Transforming Care in Tanzania
Rhea-AI Summary
Abbott's emergency medicine pioneers have provided care for over 1.2 million people, including a pregnant woman in Tanzania who needed advanced health care during heavy rains. This demonstrates the company's commitment to global healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
News
Abbott Launches New PROTALITY(TM) Brand To Support Adults on Their Weight Loss Journey
Rhea-AI Summary
Abbott (NYSE:ABT) has announced the launch of its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass and good nutrition. The shake contains 30 grams of high-quality protein, 8 essential B vitamins, 4 grams of comfort fiber, 1 gram of sugar, 150 calories, and 25 vitamins and minerals. The product is now available online and at various retailers, catering to adults interested in pursuing weight loss while maintaining muscle health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
News
Can a 'Food as Medicine' Approach Help Manage Diabetes?
Rhea-AI Summary
Abbott's partnership with the Emergency Food Bank of Stockton, Calif. has led to encouraging results in delivering healthy meal boxes to people with diabetes. Nutrition educator Alex Marapao emphasizes the use of olive oil in cooking demonstrations, promoting healthy habits to combat diabetes. The mission is to share nutrition education that takes root in the community and grows healthy habits for generations to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
-
News
New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again
Rhea-AI Summary
A new study published in the journal Transfusion reveals that Abbott and Blood Centers of America's mixed reality technology for use during blood donation helps ease donors' feelings of anxiety and boosts the likelihood they will return to give blood again. The pilot study examined the experiences of 282 blood donors who tried mixed reality at 54 collection sites in Houston and the Quad Cities area in Iowa and Illinois. 68.4% of donors who reported pre-donation anxiety said the mixed reality experience helped ease their anxiety, and 89.2% of donors who tried mixed reality said they were likely to donate blood again. The mixed reality experience is an immersive digital experience designed to improve the blood donation process, attract new donors, and motivate a younger generation to give blood. It is now available at several donation sites across the country, including in New York, Houston, and the Chicago area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
News
Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey
Rhea-AI Summary
Abbott (NYSE: ABT) has launched its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass. The brand is aimed at adults pursuing weight loss, with the first product featuring 30 grams of protein, essential B vitamins, comfort fiber, and 150 calories. The shake is now available online and at various retailers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
News
Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+
Rhea-AI Summary
Abbott (NYSE: ABT) has received FDA approval for the Liberta RC™ deep brain stimulation (DBS) system, the world's smallest rechargeable DBS device with remote programming. It offers the longest time between charges of any DBS technology on the market, requiring only 10 recharge sessions a year for most people. The system features NeuroSphere™ Virtual Clinic, allowing remote communication with doctors, ensuring proper settings and functionality, and receiving new treatment settings without visiting a doctor's office.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
Rhea-AI Summary
Abbott announced fourth-quarter sales increase of 1.5 percent, full-year 2023 reported sales decreased by 8.1 percent due to COVID-19 testing-related sales; organic sales growth increased by 11.6 percent. The company projects full-year 2024 organic sales growth to be in the range of 8.0% to 10.0%. The R&D pipeline continues to deliver new products, and the company has regained its market-leading position in the U.S. infant formula market. Abbott's new laboratory automation system, GLP systems Track™, received FDA approval, and the company's Volt™ Pulsed Field Ablation System was used for the first time in humans. Abbott's Tandem Diabetes Care's t:slim X2™ insulin pump is now the first automated insulin delivery system in the U.S. to integrate with Abbott's new FreeStyle Libre® 2 Plus sensor. The company's EPS was $3.26 for full-year 2023 and projects a diluted EPS on a GAAP basis of $3.20 to $3.40 for full-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
earnings
-
News
Continuing to Lead the Way in Sustainability
Rhea-AI Summary
Abbott has earned the top overall industry score for 11 years and leads in health access on the global sustainability benchmark DJSI. The company's 2030 Sustainability Plan aims to improve the health of 3 billion people annually by 2030, with a focus on connecting care and technology to put people in control. Abbott also achieved top scores in key social, environmental, and governance categories on the S&P Global Corporate Sustainability Assessment, confirming its position as a leader in sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
News
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Rhea-AI Summary
Abbott (ABT) announces the first global procedures using the Volt Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation. The system uses high energy electrical pulses to destroy cells causing abnormal heart rhythms, reducing the risk of damaging adjacent tissue. The Volt PFA System is designed to overcome limitations of first-generation PFA systems and provide a more accurate and efficient workflow for physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
clinical trial
Stock ABT logo
Abbott Laboratories

NYSE:ABT

ABT Rankings

#50 Ranked by Market Cap
#2392 Ranked by Stock Gains
#1403 Ranked by Dividends

ABT Stock Data

189.50B
1.72B
0.54%
77.02%
0.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Chicago

About ABT

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.